These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 3413493)
1. NCI may evaluate "alternative therapy". Holden C Science; 1988 Sep; 241(4871):1285-6. PubMed ID: 3413493 [No Abstract] [Full Text] [Related]
2. NCI accelerating prevention trend. Upton AC US Med; 1979 Jan; 15(2):59-63. PubMed ID: 10240328 [No Abstract] [Full Text] [Related]
3. NCI seeks more patients for trials. Zoler ML Med World News; 1988 Jun; 29(12):23. PubMed ID: 10287972 [No Abstract] [Full Text] [Related]
4. Cancer vaccines: the perspective of the Cancer Immunology Branch, NCI. Sogn JA; Finerty JF; Heath AK; Shen GL; Austin FC Ann N Y Acad Sci; 1993 Aug; 690():322-30. PubMed ID: 8368745 [TBL] [Abstract][Full Text] [Related]
5. Who should subsidize NCI clinical trials? Ault A Nat Med; 1998 Sep; 4(9):992. PubMed ID: 9734381 [No Abstract] [Full Text] [Related]
6. Cooperative groups say NCI trials funding inadequate; some turn to industry. Schmidt C J Natl Cancer Inst; 2007 Jun; 99(11):830-1, 837. PubMed ID: 17551138 [No Abstract] [Full Text] [Related]
8. [Past and current problems in tumor research]. von Wasielewski E; Sedlacek HH Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405 [No Abstract] [Full Text] [Related]
9. Translation of cancer immunotherapies. Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901 [No Abstract] [Full Text] [Related]
10. An open letter to cancer researchers. Elledge SJ; Hannon GJ Science; 2005 Oct; 310(5747):439-41. PubMed ID: 16239460 [No Abstract] [Full Text] [Related]
11. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435 [No Abstract] [Full Text] [Related]
13. Hatch on NCI hearings. Hatch OG Science; 1981 Jul; 213(4506):392. PubMed ID: 7244636 [No Abstract] [Full Text] [Related]
14. Embryonic stem cell research moves slowly through appeals courts, cancer trials. Jenks S J Natl Cancer Inst; 2011 Jul; 103(14):1078-9. PubMed ID: 21737694 [No Abstract] [Full Text] [Related]
15. New opportunities for the development of cancer immunotherapies. Rosenberg SA Cancer J Sci Am; 1998 May; 4 Suppl 1():S1-4. PubMed ID: 9619263 [No Abstract] [Full Text] [Related]
16. Business barriers slowing the pace of cancer immunotherapy research and development. Tuma RS J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521 [No Abstract] [Full Text] [Related]
17. US cancer institute funds trial of complementary therapy. Josefson D BMJ; 2000 Jun; 320(7251):1690. PubMed ID: 10864535 [No Abstract] [Full Text] [Related]
18. Letter: Assessing the national cancer program. Laszlo J N Engl J Med; 1975 Jul; 293(4):205-6. PubMed ID: 1134546 [No Abstract] [Full Text] [Related]
19. US cancer research strategy revised. Novak K Nat Med; 2001 Dec; 7(12):1266. PubMed ID: 11726952 [No Abstract] [Full Text] [Related]